These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

884 related articles for article (PubMed ID: 35119124)

  • 1. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
    Collins DA; Riley TV
    Lett Appl Microbiol; 2022 Sep; 75(3):526-536. PubMed ID: 35119124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ridinilazole: a novel therapy for Clostridium difficile infection.
    Vickers RJ; Tillotson G; Goldstein EJ; Citron DM; Garey KW; Wilcox MH
    Int J Antimicrob Agents; 2016 Aug; 48(2):137-43. PubMed ID: 27283730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.
    Okhuysen PC; Ramesh MS; Louie T; Kiknadze N; Torre-Cisneros J; de Oliveira CM; Van Steenkiste C; Stychneuskaya A; Garey KW; Garcia-Diaz J; Li J; Duperchy E; Chang BY; Sukbuntherng J; Montoya JG; Styles L; Clow F; James D; Dubberke ER; Wilcox M
    Clin Infect Dis; 2024 Jun; 78(6):1462-1472. PubMed ID: 38305378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of spores to prevent the recurrence of Clostridioides difficile infection - A possibility or an improbability?
    Chiu CW; Tsai PJ; Lee CC; Ko WC; Hung YP
    J Microbiol Immunol Infect; 2021 Dec; 54(6):1011-1017. PubMed ID: 34229970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ridinilazole for the treatment of Clostridioides difficile infection.
    Carlson TJ; Endres BT; Bassères E; Gonzales-Luna AJ; Garey KW
    Expert Opin Investig Drugs; 2019 Apr; 28(4):303-310. PubMed ID: 30767587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clostridioides difficile - New Insights and Therapy Recommendations].
    Schönherr S; Jung L; Lübbert C
    Dtsch Med Wochenschr; 2023 Jun; 148(12):752-758. PubMed ID: 37257477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin.
    Thorpe CM; Kane AV; Chang J; Tai A; Vickers RJ; Snydman DR
    PLoS One; 2018; 13(8):e0199810. PubMed ID: 30071046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
    Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
    Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clostridioides difficile infection: are the three currently used antibiotic treatment options equal from pharmacological and microbiological points of view?
    Krutova M; Wilcox M; Kuijper E
    Int J Infect Dis; 2022 Nov; 124():118-123. PubMed ID: 36155825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of antibiotic therapy for Clostridioides difficile infection on mortality and other patient-relevant outcomes: a systematic review and meta-analysis.
    Stabholz Y; Paul M
    Clin Microbiol Infect; 2024 Jan; 30(1):51-58. PubMed ID: 37690610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fighting against Clostridioides difficile infection: Current medications.
    Quan M; Zhang X; Fang Q; Lv X; Wang X; Zong Z
    Int J Antimicrob Agents; 2024 Jul; 64(1):107198. PubMed ID: 38734214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fidaxomicin for the treatment of
    Skinner AM; Scardina T; Kociolek LK
    Future Microbiol; 2020 Jul; 15(11):967-979. PubMed ID: 32715754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in Japan.
    Okumura H; Ueyama M; Shoji S; English M
    J Infect Chemother; 2020 Jun; 26(6):611-618. PubMed ID: 32165072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microbiome-preserving antibiotics for the treatment of Clostridioides difficile infection: a systematic review and meta-analysis.
    Kravets AM; Hanneke R; Nelson RL
    Tech Coloproctol; 2023 Dec; 28(1):20. PubMed ID: 38112980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the antimicrobial activity of ridinilazole and six comparators against Chinese, Japanese and South Korean strains of Clostridioides difficile.
    Collins DA; Wu Y; Tateda K; Kim HJ; Vickers RJ; Riley TV
    J Antimicrob Chemother; 2021 Mar; 76(4):967-972. PubMed ID: 33351917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study.
    Vickers RJ; Tillotson GS; Nathan R; Hazan S; Pullman J; Lucasti C; Deck K; Yacyshyn B; Maliakkal B; Pesant Y; Tejura B; Roblin D; Gerding DN; Wilcox MH;
    Lancet Infect Dis; 2017 Jul; 17(7):735-744. PubMed ID: 28461207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
    Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
    J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE).
    Wolf J; Kalocsai K; Fortuny C; Lazar S; Bosis S; Korczowski B; Petit A; Bradford D; Croos-Dabrera R; Incera E; Melis J; van Maanen R
    Clin Infect Dis; 2020 Dec; 71(10):2581-2588. PubMed ID: 31773143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fidaxomicin compared with vancomycin and metronidazole for the treatment of Clostridioides (Clostridium) difficile infection: A network meta-analysis.
    Okumura H; Fukushima A; Taieb V; Shoji S; English M
    J Infect Chemother; 2020 Jan; 26(1):43-50. PubMed ID: 31624029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe Clostridioides difficile infection: a retrospective, observational, nationwide cohort study.
    Gentry CA; Campbell DL; Williams RJ
    Int J Antimicrob Agents; 2021 Mar; 57(3):106282. PubMed ID: 33465458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.